{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:03:57Z","timestamp":1791644637941,"version":"4.3.4"},"reference-count":47,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"The Netherlands Organisation for Health Research and Development","doi-asserted-by":"publisher","award":["95105005"],"award-info":[{"award-number":["95105005"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,17]]},"abstract":"Abstract<\/jats:title>\n \n Context<\/jats:title>\n Synthetic glucocorticoids are widely used to treat patients with a broad range of diseases. While efficacious, glucocorticoids can be accompanied by neuropsychiatric adverse effects.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This systematic review and meta-analysis assesses and quantifies the proportion of different neuropsychiatric adverse effects in patients using synthetic glucocorticoids.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Six electronic databases were searched to identify potentially relevant studies. Randomized controlled trials, cohort studies, and cross-sectional studies assessing psychiatric side effects of glucocorticoids measured with validated questionnaires were eligible. Risk of bias was assessed with RoB 2, ROBINS-I, and AXIS appraisal tool. For proportions of neuropsychiatric outcomes, we pooled proportions, and when possible, differences in questionnaire scores between glucocorticoid users and nonusers were expressed as standardized mean differences (SMD). Data were pooled in a random-effects logistic regression model.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n We included 49 studies with heterogeneity in study populations, type, dose, and duration of glucocorticoids. For glucocorticoid users, meta-analysis showed a proportion of 22% for depression (95% CI, 14%-33%), 11% for mania (2%-46%), 8% for anxiety (2%-25%), 16% for delirium (6%-36%), and 52% for behavioral changes (42%-61%). Questionnaire scores for depression (SMD of 0.80 [95% CI 0.35-1.26]), and mania (0.78 [0.14-1.42]) were higher than in controls, indicating more depressive and manic symptoms following glucocorticoid use.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n The heterogeneity of glucocorticoid use is reflected in the available studies. Despite this heterogeneity, the proportion of neuropsychiatric adverse effects in glucocorticoid users is high. The most substantial associations with glucocorticoid use were found for depression and mania. Upon starting glucocorticoid treatment, awareness of possible psychiatric side effects is essential. More structured studies on incidence and potential pathways of neuropsychiatric side effects of prescribed glucocorticoids are clearly needed.<\/jats:p>\n <\/jats:sec>","DOI":"10.1210\/clinem\/dgad701","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T18:11:56Z","timestamp":1701281516000},"page":"e1442-e1451","source":"Crossref","is-referenced-by-count":60,"title":["Neuropsychiatric Adverse Effects of Synthetic Glucocorticoids: A Systematic Review and Meta-Analysis"],"prefix":"10.1210","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8809-2576","authenticated-orcid":false,"given":"Anne-Sophie C A M","family":"Koning","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Leiden University Medical Center , Albinusdreef 2, 2333 ZA Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0001-4408","authenticated-orcid":false,"given":"Merel","family":"van der Meulen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Leiden University Medical Center , Albinusdreef 2, 2333 ZA Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Schaap","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Leiden University Medical Center , Albinusdreef 2, 2333 ZA Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5751-8113","authenticated-orcid":false,"given":"Djaina D","family":"Satoer","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Erasmus MC\u2014University Medical Center Rotterdam , Dr. Molewaterplein 40, 3015 GD Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3698-0744","authenticated-orcid":false,"given":"Christiaan H","family":"Vinkers","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Department of Anatomy and Neurosciences, Amsterdam University Medical Center, Location VUMC , De Boelelaan 1117, 1081 HV Amsterdam , The Netherlands"},{"name":"Academic Working Place Depression, GGZ InGeest , Oldenaller 1, 1081 HJ Amsterdam , The Netherlands"},{"name":"Amsterdam Neuroscience (Mood, Anxiety, Psychosis, Stress & Sleep Program) and Amsterdam Public Health (Mental Health Program) Research Institutes , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0120-4913","authenticated-orcid":false,"given":"Elisabeth F C","family":"van Rossum","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology, Erasmus MC, University Medical Center Rotterdam , Dr. Molewaterplein 40, 3015 GD Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5208-921X","authenticated-orcid":false,"given":"Wouter R","family":"van Furth","sequence":"additional","affiliation":[{"name":"University Neurosurgical Center Holland, Leiden University Medical Center, Haaglanden Medical Center and Haga Teaching Hospitals, Leiden and The Hague , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1194-9866","authenticated-orcid":false,"given":"Alberto M","family":"Pereira","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Amsterdam University Medical Center, Location University of Amsterdam , Meibergdreef 9, 1105 AZ Amsterdam , The Netherlands"},{"name":"Amsterdam Gastroenterology Endocrinology Metabolism , Meibergdreef 9, 1105 AZ Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8394-6859","authenticated-orcid":false,"given":"Onno C","family":"Meijer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Leiden University Medical Center , Albinusdreef 2, 2333 ZA Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1333-7580","authenticated-orcid":false,"given":"Olaf M","family":"Dekkers","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Leiden University Medical Center , Albinusdreef 2, 2333 ZA Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"key":"2024051707040218200_dgad701-B1","author":"Genees- en hulpmiddelen Informatie Project (GIP) databank"},{"issue":"10","key":"2024051707040218200_dgad701-B2","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1176\/appi.ajp.2014.13091264","article-title":"Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects","volume":"171","author":"Judd","year":"2014","journal-title":"Am J Psychiatry"},{"issue":"5","key":"2024051707040218200_dgad701-B3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1176\/appi.ajp.2011.11071009","article-title":"Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care","volume":"169","author":"Fardet","year":"2012","journal-title":"Am J Psychiatry"},{"issue":"4","key":"2024051707040218200_dgad701-B4","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1210\/endo.139.4.5917","article-title":"Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice","volume":"139","author":"Meijer","year":"1998","journal-title":"Endocrinology"},{"issue":"3-4","key":"2024051707040218200_dgad701-B5","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1159\/000501617","article-title":"Systemic and local corticosteroid use is associated with reduced executive cognition, and mood and anxiety disorders","volume":"110","author":"Savas","year":"2020","journal-title":"Neuroendocrinology"},{"issue":"8","key":"2024051707040218200_dgad701-B6","doi-asserted-by":"crossref","first-page":"e062446","DOI":"10.1136\/bmjopen-2022-062446","article-title":"Association between use of systemic and inhaled glucocorticoids and changes in brain volume and white matter microstructure: a cross-sectional study using data from the UK Biobank","volume":"12","author":"van der Meulen","year":"2022","journal-title":"BMJ Open"},{"issue":"8","key":"2024051707040218200_dgad701-B7","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1038\/s41591-022-01949-2","article-title":"Metabolomic profiling reveals extensive adrenal suppression due to inhaled corticosteroid therapy in asthma","volume":"28","author":"Kachroo","year":"2022","journal-title":"Nat Med"},{"issue":"6","key":"2024051707040218200_dgad701-B8","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrn1683","article-title":"Stress and the brain: from adaptation to disease","volume":"6","author":"de Kloet","year":"2005","journal-title":"Nat Rev Neurosci"},{"key":"2024051707040218200_dgad701-B9","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.pnpbp.2017.11.020","article-title":"Glucocorticoids, genes and brain function","volume":"82","author":"Juszczak","year":"2018","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"4","key":"2024051707040218200_dgad701-B10","doi-asserted-by":"crossref","first-page":"e13125","DOI":"10.1111\/jne.13125","article-title":"Gene expression changes in the brain of a Cushing's syndrome mouse model","volume":"34","author":"Amaya","year":"2022","journal-title":"J Neuroendocrinol"},{"issue":"3","key":"2024051707040218200_dgad701-B11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1530\/eje.0.1510397","article-title":"Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties","volume":"151","author":"Grossmann","year":"2004","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2024051707040218200_dgad701-B12","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1038\/s41467-020-17429-5","article-title":"The circadian phase of antenatal glucocorticoid treatment affects the risk of behavioral disorders","volume":"11","author":"Astiz","year":"2020","journal-title":"Nat Commun"},{"issue":"3","key":"2024051707040218200_dgad701-B13","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1210\/en.2016-1495","article-title":"A refill for the brain mineralocorticoid receptor: the benefit of cortisol add-on to dexamethasone therapy","volume":"158","author":"Meijer","year":"2017","journal-title":"Endocrinology"},{"issue":"3","key":"2024051707040218200_dgad701-B14","doi-asserted-by":"crossref","first-page":"e210425","DOI":"10.1530\/EC-21-0425","article-title":"Mineralocorticoid receptor status in the human brain after dexamethasone treatment: a single case study","volume":"11","author":"Koning","year":"2022","journal-title":"Endocr Connect"},{"key":"2024051707040218200_dgad701-B15","doi-asserted-by":"crossref","first-page":"960279","DOI":"10.3389\/fendo.2022.960279","article-title":"Dexamethasone-associated metabolic effects in male mice are partially caused by depletion of endogenous corticosterone","volume":"13","author":"Koorneef","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"19","key":"2024051707040218200_dgad701-B16","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1200\/JCO.2015.66.0761","article-title":"Hydrocortisone as an intervention for dexamethasone-induced adverse effects in pediatric patients with acute lymphoblastic leukemia: results of a double-blind, randomized controlled trial","volume":"34","author":"Warris","year":"2016","journal-title":"J Clin Oncol"},{"key":"2024051707040218200_dgad701-B17","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejca.2023.03.039","article-title":"Hydrocortisone to reduce dexamethasone-induced neurobehavioral side-effects in children with acute lymphoblastic leukaemia-results of a double-blind, randomised controlled trial with cross-over design","volume":"187","author":"van Hulst","year":"2023","journal-title":"Eur J Cancer"},{"issue":"1","key":"2024051707040218200_dgad701-B18","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s12887-021-02896-6","article-title":"Study protocol: DexaDays-2, hydrocortisone for treatment of dexamethasone-induced neurobehavioral side effects in pediatric leukemia patients: a double-blind placebo controlled randomized intervention study with cross-over design","volume":"21","author":"van Hulst","year":"2021","journal-title":"BMC Pediatr"},{"issue":"12","key":"2024051707040218200_dgad701-B19","doi-asserted-by":"crossref","first-page":"e054405","DOI":"10.1136\/bmjopen-2021-054405","article-title":"The DEXA-CORT trial: study protocol of a randomised placebo-controlled trial of hydrocortisone in patients with brain tumour on the prevention of neuropsychiatric adverse effects caused by perioperative dexamethasone","volume":"11","author":"Koning","year":"2021","journal-title":"BMJ Open"},{"issue":"5","key":"2024051707040218200_dgad701-B20","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.semarthrit.2020.06.019","article-title":"The patient's perspective of the adverse effects of glucocorticoid use: a systematic review of quantitative and qualitative studies. From an OMERACT working group","volume":"50","author":"Cheah","year":"2020","journal-title":"Semin Arthritis Rheu"},{"key":"2024051707040218200_dgad701-B21","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2024051707040218200_dgad701-B22","author":"Koning"},{"key":"2024051707040218200_dgad701-B23","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2024051707040218200_dgad701-B24","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"12","key":"2024051707040218200_dgad701-B25","doi-asserted-by":"crossref","first-page":"e011458","DOI":"10.1136\/bmjopen-2016-011458","article-title":"Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS)","volume":"6","author":"Downes","year":"2016","journal-title":"BMJ Open"},{"key":"2024051707040218200_dgad701-B26","volume-title":"Statistical Power Analysis for the Behavioural Sciences. 2nd edn","author":"Cohen","year":"1988"},{"key":"2024051707040218200_dgad701-B27","author":"West"},{"key":"2024051707040218200_dgad701-B28","author":"Wickham"},{"key":"2024051707040218200_dgad701-B29","author":"Schwarzer"},{"issue":"12","key":"2024051707040218200_dgad701-B30","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/ard.2008.100008","article-title":"Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis","volume":"68","author":"Hoes","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"2024051707040218200_dgad701-B31","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1136\/ard.2009.124958","article-title":"Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice","volume":"69","author":"Van der Goes","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2024051707040218200_dgad701-B32","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1365-2133.2007.07950.x","article-title":"Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion","volume":"157","author":"Fardet","year":"2007","journal-title":"Br J Dermatol"},{"issue":"6","key":"2024051707040218200_dgad701-B33","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1440-1819.2011.02260.x","article-title":"Psychiatric complications of treatment with corticosteroids: review with case report","volume":"65","author":"Kenna","year":"2011","journal-title":"Psychiatry Clin Neurosci"},{"issue":"4","key":"2024051707040218200_dgad701-B34","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0165-0327(83)90022-8","article-title":"Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature","volume":"5","author":"Lewis","year":"1983","journal-title":"J Affect Disord"},{"issue":"5","key":"2024051707040218200_dgad701-B35","first-page":"998","article-title":"Psychological aspects of systemic lupus erythematosus: cognitive function, mood, and self-report","volume":"24","author":"Denburg","year":"1997","journal-title":"J Rheumatol"},{"issue":"12","key":"2024051707040218200_dgad701-B36","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/art.1780391213","article-title":"Analysis of cognitive and psychological deficits in systemic lupus erythematosus patients without overt central nervous system disease","volume":"39","author":"Kozora","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2024051707040218200_dgad701-B37","doi-asserted-by":"crossref","first-page":"e13213","DOI":"10.1111\/jne.13213","article-title":"Transcriptional glucocorticoid effects in the brain: finding the relevant target genes","volume":"35","author":"Meijer","year":"2023","journal-title":"J Neuroendocrinol"},{"issue":"2","key":"2024051707040218200_dgad701-B38","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/joim.13056","article-title":"Psychiatric and neurocognitive consequences of endogenous hypercortisolism","volume":"288","author":"Piasecka","year":"2020","journal-title":"J Intern Med"},{"issue":"1-3","key":"2024051707040218200_dgad701-B39","first-page":"30","article-title":"Psychiatric symptoms in Cushing's syndrome: a systematic review","volume":"17","author":"Lin","year":"2020","journal-title":"Innov Clin Neurosci"},{"issue":"1","key":"2024051707040218200_dgad701-B40","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1749-6632.2009.04985.x","article-title":"Glucocorticoid receptor polymorphisms in major depression. Focus on glucocorticoid sensitivity and neurocognitive functioning","volume":"1179","author":"Spijker","year":"2009","journal-title":"Ann New York Acad Sci"},{"issue":"11","key":"2024051707040218200_dgad701-B41","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1159\/000513703","article-title":"Anthropometrics and metabolic syndrome in relation to glucocorticoid receptor polymorphisms in corticosteroid users","volume":"111","author":"Savas","year":"2020","journal-title":"Neuroendocrinology"},{"issue":"6","key":"2024051707040218200_dgad701-B42","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1210\/jc.2015-1218","article-title":"Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis","volume":"100","author":"Broersen","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2024051707040218200_dgad701-B43","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1038\/tp.2011.59","article-title":"A common and functional mineralocorticoid receptor haplotype enhances optimism and protects against depression in females","volume":"1","author":"Klok","year":"2011","journal-title":"Transl Psychiatry"},{"issue":"5","key":"2024051707040218200_dgad701-B44","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.psyneuen.2010.10.003","article-title":"Human mineralocorticoid receptor (MR) gene haplotypes modulate MR expression and transactivation: implication for the stress response","volume":"36","author":"van Leeuwen","year":"2011","journal-title":"Psychoneuroendocrino"},{"key":"2024051707040218200_dgad701-B45","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.psyneuen.2016.11.037","article-title":"Mineralocorticoid receptor haplotype, estradiol, progesterone and emotional information processing","volume":"76","author":"Hamstra","year":"2017","journal-title":"Psychoneuroendocrino"},{"issue":"3","key":"2024051707040218200_dgad701-B46","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ando.2018.03.004","article-title":"Glucocorticoid receptor modulators","volume":"79","author":"Meijer","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"issue":"3","key":"2024051707040218200_dgad701-B47","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000499659","article-title":"Corticosteroid action in the brain: the potential of selective receptor modulation","volume":"109","author":"Viho","year":"2019","journal-title":"Neuroendocrinology"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad701\/54527101\/dgad701.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/6\/e1442\/57709069\/dgad701.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/6\/e1442\/57709069\/dgad701.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T03:05:40Z","timestamp":1715915140000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/109\/6\/e1442\/7457344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":47,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,12,1]]},"published-print":{"date-parts":[[2024,5,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad701","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2023,12,1]]}}}